Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced an amendment extending the non-disclosure deadline for the counterparty of a contract manufacturing LOI signed with a European pharmaceutical company to June 30, 2024, in consultation with the client.
📊 [Key Disclosure Details & Summary Statistics]
- Disclosure Type: Correction Report (Original Disclosure Date: 2023-05-30)
- Reason for Correction: Modification of non-disclosure date in consultation with the client
- Corrected Item (Non-Disclosure Postponement Date):
- Postponement Deadline for Counterparty Disclosure: (Before) 2024-05-31 → (After) 2024-06-30
- Summary of Original Disclosure (Execution of Contract Manufacturing LOI):
- Counterparty: Pharmaceutical company located in Europe (Undisclosed due to trade secrecy)
- Contract Amount: KRW 107,513,583,360 (KRW ~107.5B) / USD 81,105,600
- Contract Ratio to Recent Annual Revenue: 3.58% (Based on 2022 annual revenue of KRW 3,001,295,197,683)
- LOI Execution Date: May 30, 2023
- Board Resolution Date or Fact Confirmation Date: May 30, 2023
- Other Key Investment Matters:
- The contract amount was converted using the initial FX rate of USD/KRW 1,325.60 on May 30, 2023, based on the confirmed amount of USD 81,105,600.
- The agreement is legally binding between both parties, and definitive details will be disclosed upon execution of the main contract.
- The contract period is from the date of LOI execution until the execution of the main contract.
- Counterparty details will be disclosed upon execution of the main contract due to business trade secrecy.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Execution of Main Contract and Non-Disclosure Extensions
This amendment reflects an extension of the counterparty non-disclosure deadline to June 30, 2024, in consultation with the client. Checking whether a definitive main contract disclosure is filed within the revised deadline—or if further amendments are submitted to modify the period—is important for understanding the progress and finalization status of the transaction. Relevant updates can be verified through subsequent disclosures or periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
